Current Evidence and Guidelines for Anti-SARS-CoV-2 Monoclonal Antibodies

Target Audience

The educational design of this activity addresses the needs of infectious disease clinicians, internal medicine clinicians, and primary care providers, including physicians, nurse practitioners, and physician assistants, involved in the care of patients with mild or moderate coronavirus disease 2019 (COVID-19) who are at risk for clinical progression (eg, older patients, immunocompromised patients, patients with certain comorbidities).

Statement of Need/Program Overview

As therapeutic options to treat mild or moderate COVID-19 in patients at high risk of progression to severe disease continue to evolve, clinicians must be kept up to date on the latest therapies and guidelines. Emerging variants and subvariants can affect efficacy of therapies to manage COVID-19, particularly anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs). Guidelines from the National Institutes of Health are frequently updated to reflect the ever-changing status of the COVID-19 pandemic. Drs. Monica Gandhi and Lucy Horton discuss recent clinical trial data supporting Emergency Use Authorizations (EUAs) for anti-SARS-CoV-2 mAbs, EUA criteria, and the effect of the Omicron variant on the course of the pandemic as well as the efficacy of available mAbs.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the clinical profiles, trial data, and regulatory status of current anti-SARS-CoV-2 monoclonal antibodies
• Identify patients who qualify for anti-SARS-CoV-2 monoclonal antibody therapy based on current national guidelines

Faculty

Monica Gandhi, MD, MPH
Professor of Medicine and Associate Chief
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco (UCSF) School of Medicine
Director, UCSF-Bay Area Center for AIDS Research (CFAR)
Medical Director
“Ward 86” HIV Clinic, San Francisco General Hospital
San Francisco, California

Lucy Horton, MD, MPH
Associate Professor of Medicine
Division of Infectious Diseases and Global Health
University of California San Diego School of Medicine
Medical Director and Infectious Disease Specialist
COVID-19 Employee Health and Contact Tracing Group
Ambulatory COVID Drive Up and Results Team Services
UC San Diego Health
San Diego, California

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour(s) (which includes 0.1 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 100% on the posttest, and complete the program evaluation.

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Gandhi, MD, MPH: Nothing to disclose

Lucy Horton, MD, MPH: Consulting Fee: Gilead Sciences, Inc., GlaxoSmithKline

The following planners and managers have no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Rose O'Connor, PhD, CHCP, Jim Kappler, PhD

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)